MSH|^~\&|txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|txdshslab^2.16.840.1.114222.4.1.181960^ISO|OrderingApplicationName^2.16.840.1.114222.XXX^ISO|OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20190720091229||ORU^R01^ORU_R01|DSHS123456789012345|P|2.5.1|||AL|AL
PID|1||123456^^^^MR||BabyLast^BabyFirst|MotherMaiden|201907011118|F^Female^HL70001||2028-9^Asian^HL70005~2106-3^White^HL70005||||||||ABCD1234^^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^AN|||223456^^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^MR|N|Birth Hospital Name|Y|1
NK1|1|MotherLast^MotherFirst|MTH^Mother^HL70063|123 SUNSHINE DR^^AUSTIN^TX^78756|^^PH^^^555^5554321||N^Next of Kin^HL70131|||||||||19901115|||||||||||||||||123456789^^^txMCDmedIDadm&2.16.840.1.113883.4.446&ISO^MA
ORC|RE|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|25^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|CM||||20190724160530|||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L^^^NPI|||20190720090030||||||ORDERING FACILITY NAME^^^^^txdshslabNBS&2.16.840.1.114222.4.1.181960.2&ISO^FI^^^01234567|123 Main Street^^Austin^TX^78758|^^PH^^^512^5551212
OBR|1|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|57128-1^Newborn Screening report summary panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
NTE|1|L^Ancillary (filler) department is source of comment^HL70105|The newborn screen identifies newborns at increased risk for specified disorders. The reference value for all screened disorders is ‘Normal’. Analyte results are only listed for abnormal disorder screening results. The recommended collection time period and the testing methodologies have been designed to minimize the number of false negative and false positive results in newborns and young infants. When the newborn screen specimen is collected before 24 hours of age or on older children, the test may not identify some of these conditions. If there is a clinical concern, diagnostic testing should be initiated. Specimens that are unacceptable are reported as Unsatisfactory|RE^Remark^HL70364 NTE|2|L^Ancillary (filler) department is source of comment^HL70105|The SCID / TREC (T-cell receptor excision circles) test is performed by quantitative real-time polymerase chain reaction analysis to detect the number of TRECs. SCID, Biotinidase deficiency, and Hemoglobinopathy screening tests were developed /modified and performance characteristics determined by DSHS. These tests have not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such approval is not necessary if performance characteristics are verified at the testing laboratory.|RE^Remark^HL70364
NTE|3|L^Ancillary (filler) department is source of comment^HL70105|Disorders Screened: AMINO ACID DISORDERS: ARG, ASA, CIT, CIT II, BIOPT(BS), BIOPT(REG), HCY, H-PHE, MET, MSUD, PKU, TYRI, TYRII, and TYRIII. FATTY ACID DISORDERS: CACT, CPT IA, CPT II, CUD, DE RED, GA2, LCHAD, MCAD, MCAT, M/SCHAD, SCAD, TFP, VLCAD. ORGANIC ACID DISORDERS: 2M3HBA, 2MBG, 3MCC, 3MGA, BKT, GA1, HMG, IBG, IVA, MAL, MMA (MUT, Cbl A, B, C, D), MCD, PROP. GALACTOSEMIA. BIOTINIDASE DEFICIENCY. HYPOTHYROIDISM. CAH. HEMOGLOBINOPATHIES: Hb S/S, Hb S/C, Hb SBeta Th, Var Hb. CYSTIC FIBROSIS. SCID and T-Cell related Lymphopenias. X-ALD. List of disorders screened available at www.dshs.state.tx.us/lab/NBSdisorderList.pdf|RE^Remark^HL70364
NTE|4|L^Ancillary (filler) department is source of comment^HL70105|For more information, please refer to http://www.dshs.state.tx.us/lab/newbornscreening.shtm|RE^Remark^HL70364
NTE|5|L^Ancillary (filler) department is source of comment^HL70105|The Cystic Fibrosis molecular testing panel consists of 60 mutations and 4 variants in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene and is performed using the Luminex xTAG Cystic Fibrosis (CFTR) 60 kit v2 assay. Depending on the patient's ethnicity, the mutation detection rate is estimated to be 54.5-95.9% and the residual risk of carrying a CFTR mutation not included on the panel is approximately 0.2-0.5%. Test results should not be used to diagnose but should be interpreted in the context of clinical findings, family history, and other laboratory data.|RE^Remark^HL70364
OBX|1|CWE|57718-9^Sample quality of Dried blood spot^LN||LA12432-3^Acceptable^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|2|CWE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN^^^^^^Abnormal|||A|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|3|CWE|57131-5^Newborn conditions with positive markers [Identifier] in DBS^LN|1|LA21161-7^Argininemia^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|4|CWE|57131-5^Newborn conditions with positive markers [Identifier] in DBS^LN|2|LA12566-8^Severe combined immunodeficiency^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|5|CWE|57131-5^Newborn conditions with positive markers [Identifier] in DBS^LN|3|LA25796-6^X-linked adrenoleukodystrophy^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|6|CWE|57720-5^Newborn conditions with equivocal markers [Identifier] in DBS^LN|1|LA22202-8^Cystic fibrosis^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|7|ST|57724-7^Newborn screening short narrative summary^LN||SUMMARY: Abnormal\.br\Sample Quality: Acceptable\.br\Amino Acid Disorders: Abnormal - Possible Amino Acid Disorder. Arginine Slightly Elevated. If this is the second screen, follow recommendations received from Clinical Care Coordination. Otherwise, repeat the newborn screen within 7 days.\.br\Fatty Acid Disorders: Normal\.br\Organic Acid Disorders: Normal\.br\Galactosemia: Normal\.br\Biotinidase Deficiency: Normal\.br\Hypothyroidism: Normal\.br\CAH: Normal\.br\Hemoglobinopathies: Normal\.br\Cystic Fibrosis: Inconclusive - No further evaluation necessary unless clinically indicated. Immunoreactive Trypsinogen (IRT) Elevated. None of the CFTR variants in the DSHS panel were detected. However, there is a minimal risk for Cystic Fibrosis due to variants not included in the panel.\.br\SCID: Abnormal - Possible Severe Combined Immunodeficiency or other T-cell lymphopenia. T-cell receptor excision circles (TREC) number Very Low. Follow recommendations received from Clinical Care Coordination.\.br\XALD: Abnormal - Possible X-ALD. C26:0 LPC Elevated. Recommend confirmatory very long chain fatty acids and consultation with a pediatric metabolic specialist or pediatric neurogeneticist within 7 days. DNA report to follow.|||A|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
SPM|1|SID20192019999&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001&txdshslabNBS&2.16.840.1.114222.4.1.181960.2&ISO|SID20192019999^OrderingFacilityName&2.16.840.1.114222.XXX^ISO|440500007^Blood spot specimen^SCT|||CAP^Capillary Specimen^HL70396||||||||||201907200835|201907210000|||||||LA12432-3^Acceptable^LN||||||20192024001^^^txdshslabNBS&2.16.840.1.114222.4.1.181960.2&ISO^ACSN~000002019201009999^^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^ACSN|190123456^^^txdshslab&2.16.840.1.114222.4.1.181960&ISO^SID
OBR|2|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|57717-1^Newborn screen card data panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|TX|57723-9^Unique bar code number of Current sample^LN||190123456||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||SCI
OBX|2|NM|8339-4^Birthweight^LN||2805|g^gram^UCUM|||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA &2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||SCI
OBX|3|CWE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN||LA12419-0^Infant in NICU at time of specimen collection^LN^^^^^^SICK/PREMATURE||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||SCI
OBX|4|CWE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN||LA12420-8^Systemic antibiotics before newborn screening^LN^^^^^^ON MEDICATIONS||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||SCI
OBX|5|CWE|67704-7^Feeding types^LN||LA16914-6^Breast milk^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||SCI
OBX|6|CWE|67704-7^Feeding types^LN||LA16915-3^Lactose formula^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||SCI
OBX|7|TX|62324-9^Post-discharge provider name^LN||Healthy,Bob||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^ CLIA &2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||QST
OBX|8|XTN|62328-0^Post-discharge provider practice telephone number^LN|1|^^PH^^^555^5551212^||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||QST
OBR|3|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|53261-4^Amino acid newborn screen panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46733-2^Amino acidemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN^^^^^^Abnormal|||A|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|2|CWE|57793-2^ Amino acidemia disorder suspected [Identifier] in Dried blood spot^LN|1|LA21161-7^Argininemia^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|3|TX|57710-6^Amino acidemias newborn screening comment-discussion^LN|1|Possible Amino Acid Disorder. Arginine Slightly Elevated. If this is the second screen, follow recommendations received from Clinical Care Coordination. Otherwise, repeat the newborn screen within 7 days.||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|4|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|57084-6^Fatty acid oxidation newborn screen panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46736-5^Fatty acid oxidation defects newborn screen interpretation^LN|1|LA18592-8^In range^LN^^^^^^Normal|||N|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|2|CWE|57792-4^FA oxidation conditions suspected DBS^LN|1|LA137-2^None^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|5|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|57085-3^Organic acid newborn screen panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46744-9^Organic acidemias newborn screen interpretation^LN||LA18592-8^In range^LN^^^^^^Normal|||N|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|2|CWE|57791-6^Organic acidemia conditions suspected [Identifier] in Dried blood spot^LN||LA137-2^None^LN||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|6|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|54078-1^Cystic fibrosis newborn screening panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA9663-1^Inconclusive^LN^^^^^^Inconclusive|||A|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|2|TX|57707-2^Cystic fibrosis newborn screening comment- discussion^LN|1|No further evaluation necessary unless clinically indicated. Immunoreactive Trypsinogen (IRT) Elevated. None of the CFTR variants in the DSHS panel were detected. However, there is a minimal risk for Cystic Fibrosis due to variants not included in the panel.||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|7|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|57086-1^Congenital adrenal hyperplasia newborn screening panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN^^^^^^Normal|||N|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|8|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|54090-6^Thyroid newborn screening panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN^^^^^^Normal|||N|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|9|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|54079-9^Galactosemia newborn screen panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN^^^^^^Normal|||N|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|10|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|54081-5^Hemoglobinopathies newborn screen panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46740-7^Hemoglobin disorders newborn screening interpretation^LN|1|LA18592-8^In range^LN^^^^^^Normal|||N|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|11|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|57087-9^Biotinidase Newborn Screen Panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN^^^^^^Normal|||N|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|12|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|62333-0^Severe combined immunodeficiency (SCID) newborn screen panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|62321-5^Severe combined immunodeficiency (SCID) newborn screen interpretation^LN|1|LA18593-6^Out of range^LN^^^^^^Abnormal|||A|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|2|TX|62322-3^Severe combined immunodeficiency (SCID) newborn screening commentdiscussion^LN|1|Possible Severe Combined Immunodeficiency or other T-cell lymphopenia. T-cell receptor excision circles (TREC) number Very Low. Follow recommendations received from Clinical Care Coordination.||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBR|13|123456^OrderingFacilityName^2.16.840.1.114222.XXX^ISO|20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO|85267-3^X-linked adrenoleukodystrophy (X-ALD) newborn screen panel^LN|||201907200835|||12188^Hippocrates^Harold^H^IV^Dr^MD^^OrderingFacilityName&2.16.840.1.114222.XXX&ISO^L^^EI|G||F^Patient fasting prior to procedure^HL70916|201907210000||1234567890^Dolittle^John^Q^JR^DR^^^NPI&2.16.840.1.113883.4.6&ISO^L||PlacerField1|PlacerField2|||20190724160054||LAB|F||||123456&OrderingFacilityName&2.16.840.1.114222.XXX&ISO^20192024001^txdshslabNBS^2.16.840.1.114222.4.1.181960.2^ISO||||||||||^difficulty collecting sample||||||||NDBS||A^Alert provider when abnormal^HL70507|54089-8^Newborn screening panel American Health Information Community (AHIC)^LN
OBX|1|CWE|85269-9^X-linked adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN|1|LA18593-6^Out of range^LN^^^^^^Abnormal|||A|||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
OBX|2|TX|85268-1^X-linked adrenoleukodystrophy (X-ALD) newborn screening commentdiscussion^LN|1|Possible X-ALD. C26:0 LPC Elevated. Recommend confirmatory very long chain fatty acids and consultation with a pediatric metabolic specialist or pediatric neurogeneticist within 7 days. DNA report to follow.||||||F|||201907200835|||||20190724160054||||Texas Department of State Health Services Laboratory Services Section^^^^^CLIA&2.16.840.1.113883.4.7&ISO^LN^^^45D0660644|1100 W.49th St^^Austin^TX^78756^USA^SL^^453|||||RSLT
